The upcoming pancreatic cancer data presentation will provide comprehensive data on efficacy, safety, and biomarkers. Promising results may lead to a new cohort receiving standard care and NBTXR3. Nanobiotix's remaining costs in the NANORAY study are minimal, covered mostly by J&J.